NCT04972721

SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial

SELECT-LIFE (SELECT Follow-up Study to Evaluate Long-term Impact oF Anti-obEsity Medication)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3,439 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

Participants are being asked to participate in SELECT-LIFE study because participants take part in the SELECT trial. SELECT-LIFE study is a survey-based study that will start when the SELECT trial ends. SELECT-LIFE looks at the long-term effects of participants taking part in the SELECT trial including the trial medicine participants have been taking. When the SELECT trial ends, participants will no longer get the medicine participants got in the study, even if participants decide to take part in the SELECT-LIFE study. Participants will not get any specific treatment or medicine as part of the SELECT-LIFE study, and participants will be treated as participants normally would by their own doctor. The SELECT-LIFE study will last for up to 10 years after SELECT trial ends, and participants will be asked to fill in a questionnaire about their health every 6 months.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
OTHER	No treatment given	The study is non-interventional with no study-specific treatment during the study and the patients will be treated as per Treating Physician's and patient's own discretion.

Timeline

• Start date: 2023-09-01
• Primary completion: 2025-08-25
• Completion: 2025-08-25
• First posted: 2021-07-22
• Last updated: 2026-02-11

Locations

38 sites across 24 countries: United States, Algeria, Argentina, Australia, Brazil, Canada, Croatia, Denmark, Finland, Germany, Greece, India, Ireland, Italy, Japan, Latvia, Malaysia, Netherlands, Norway, South Africa, Sweden, Taiwan, Thailand, United Kingdom